Nothing Special   »   [go: up one dir, main page]

AU2001261023A1 - Use of an ampa receptor potentiator for the treatment of obesity - Google Patents

Use of an ampa receptor potentiator for the treatment of obesity

Info

Publication number
AU2001261023A1
AU2001261023A1 AU2001261023A AU6102301A AU2001261023A1 AU 2001261023 A1 AU2001261023 A1 AU 2001261023A1 AU 2001261023 A AU2001261023 A AU 2001261023A AU 6102301 A AU6102301 A AU 6102301A AU 2001261023 A1 AU2001261023 A1 AU 2001261023A1
Authority
AU
Australia
Prior art keywords
obesity
treatment
ampa receptor
receptor potentiator
potentiator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261023A
Inventor
Phil Skolnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001261023A1 publication Critical patent/AU2001261023A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001261023A 2000-05-24 2001-05-11 Use of an ampa receptor potentiator for the treatment of obesity Abandoned AU2001261023A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20666200P 2000-05-24 2000-05-24
US60/206,662 2000-05-24
PCT/US2001/011769 WO2001089510A2 (en) 2000-05-24 2001-05-11 Use of an ampa receptor potentiator for the treatment of obesity

Publications (1)

Publication Number Publication Date
AU2001261023A1 true AU2001261023A1 (en) 2001-12-03

Family

ID=22767386

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261023A Abandoned AU2001261023A1 (en) 2000-05-24 2001-05-11 Use of an ampa receptor potentiator for the treatment of obesity

Country Status (2)

Country Link
AU (1) AU2001261023A1 (en)
WO (1) WO2001089510A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089848A2 (en) * 2001-05-04 2002-11-14 Eli Lilly And Company Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
WO2003032974A2 (en) * 2001-10-12 2003-04-24 Eli Lilly And Company Use of sulfonamide derivatives as pharmaceuticals compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
PE20000944A1 (en) * 1998-07-31 2000-09-20 Lilly Co Eli SULFONAMIDE DERIVATIVES
WO2000006537A1 (en) * 1998-07-31 2000-02-10 Eli Lilly And Company N-substituted sulfonamide derivatives

Also Published As

Publication number Publication date
WO2001089510A3 (en) 2002-07-25
WO2001089510A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
AU2935200A (en) Compounds for the treatment of obesity
HK1047284A1 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity
AU2001243462A1 (en) Improved thoraco-lumbo-sacral orthosis
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
AU2002348226A1 (en) Invasive therapeutic probe
AU2002222853A1 (en) Therapeutic compounds
AU1260401A (en) Thumb splint
AU2002341963A1 (en) Flushable commode liner
AU2001253070A1 (en) Isoflavones for treatment of obesity
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
AU2001272974A1 (en) Human receptors
AU2002353739A1 (en) Therapeutic compounds
AU2001264920A1 (en) Therapeutic uses of il-1 receptor antagonist
AU2002236781A1 (en) Treatment for snoring
AU2003236649A1 (en) Egf receptor antagonists in the treatment of gastric cancer
AU2001261023A1 (en) Use of an ampa receptor potentiator for the treatment of obesity
AU2002355919A1 (en) Massage apparatus for bowels
AU2003264297A1 (en) Use of vanilloid receptor antagonists for the treatment of pain
AU2002336782A1 (en) Penis vibrator
AU2000272704A1 (en) Use of compounds for the treatment of obesity
AU2002367305A1 (en) Foot orthosis
AU2002315522A1 (en) Receptor agonists useful for the treatment of pain
AU2003300867A1 (en) Uses of the snorf207 receptor
AU5621501A (en) Regulation of human ephrin-like receptor
AU2002309243A1 (en) Heterocyclic compounds for therapeutic use